IntraBio’s team translates research into potential treatments that aim to significantly improve the lives of patients, their caregivers, and families.
IntraBio’s investigational lead drug, IB1001, is an orally administered, modified amino acid (N-Acetyl-L-Leucine) with the potential to provide a meaningful advance in the treatment paradigm for rare neurodegenerative diseases.
Details of IntraBio’s clinical studies are published in the world’s leading medical journals.
